Hepatitis C virus (HCV) is a global health problem, because infection frequently leads to chronic hepatitis C eventually progressing to liver cirrhosis and liver cancer. Improved insights into the HCV replication cycle and the role of HCV non-structural proteins have recently enabled to identify drugs directly acting on specific HCV target structures. Agents from three drug classes have been developed and approved by the health authorities. Combinations of two or more drugs from different classes achieve high (> 90%) HCV clearance rates and are well tolerated. This interferon-free DAA (direct antiviral agent) therapy has revolutionized antiviral therapy in hepatitis C so that successful hepatitis C treatment can be offered to virtually all patients irrespective of their co-morbidity. This review provides an overview over currently approved regimens and outlines their use in clinical practice. In addition potential short-comings of the current therapeutic options such as drug-drug interactions and selection of viral resistance are addressed. DAA combination therapy has the potential to obtain global control over hepatitis C. However, easy access to DAAs, availability of reliable HCV diagnostics, and affordable costs remain still important goals, which must be reached to globally eliminate hepatitis C.

丙型肝炎病毒（HCV）是全球性的健康问题，因为感染经常导致慢性丙型肝炎，最终发展为肝硬化和肝癌。最近，人们对HCV复制周期和HCV非结构蛋白的作用有了更深入的了解，从而能够鉴定直接作用于特定HCV靶标结构的药物。卫生当局已经开发并批准了来自三种药物类别的药物。两种或多种不同类别药物的组合可实现高（> 90％）HCV清除率，并且耐受性良好。这种无干​​扰素的DAA（直接抗病毒药）疗法彻底改变了丙型肝炎的抗病毒治疗，因此几乎可以将所有患者（不论其合并症）提供成功的丙型肝炎治疗。这篇综述概述了当前批准的治疗方案，并概述了它们在临床实践中的用途。另外，解决了当前治疗选择的潜在缺点，例如药物-药物相互作用和病毒抗性的选择。DAA组合疗法有可能获得对丙型肝炎的全面控制。然而，易于获得DAA，可靠的HCV诊断的可用性以及可负担的费用仍然是重要的目标，必须实现这些目标才能在全球范围内消除丙型肝炎。